Developmental therapeutics program at the NCI: Molecular target and drug discovery process

Leukemia

Volumn 16, Issue 4, 2002, Pages 520-526

  Monga, M ^a   Sausville, E A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics program; Drug development; Drug discovery; Molecular target

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBANILAMIDE DERIVATIVE; DEPSIPEPTIDE; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PERIFOSINE; RAPAMYCIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CENTER; CELL LINE; DATA BASE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PUBLIC HEALTH SERVICE; REPRODUCIBILITY; REVIEW; SCREENING TEST; SOLID TUMOR; SYNTHESIS; TIME; TUMOR CELL;

EID: 0036233675     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402464     Document Type: Review

References (31)

1. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA
2. Role of the national cancer institute in acquired immunodeficiency syndrome-related drug discovery
3. Selection of molecular fragment features for structure-activity studies in antitumor screening
4. The pre-clinical new drug research program of the National Cancer Institute
5. Feasibility of drug screening with panels of human tumor cell lines using a micro culture tetrazolium assay
6. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
7. In vivo cultivation of tumor cells in hollow fibers
8. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
9. The hollow fiber assay: Continued characterization with novel approaches
10. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
11. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
12. An information-intensive approach to the molecular pharmacology of cancer
13. A gene expression database for the molecular pharmacology of cancer
14. Enhanced sensitivity to 1-beta-D-arabinofurano-sylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes
15. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
16. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs
17. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by including apoptosis
18. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
19. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
20. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
21. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
22. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
23. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia
24. Flavopiridol-induced apoptosis is associated with a decrease in cyclin D1 in mantle lymphoma cell lines
25. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
26. Phase I clinical and pharmokinetic trial of flavopiridol
27. A phase IB clinical trial of the sequence dependent combination of paclitaxel (P) and cisplatin (C) with cyclin dependent kinase (CDK) inhibitor flavopiridol in patients with advanced solid tumors
28. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
29. Phase I trial of 7-hydroxystaurosporine (UCN-01) and fludarabine phosphate; in vivo evidence of UCN-01 induced apoptosis in CLL
30. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
31. A phase I study of FR901228 (Depsipeptide), a histone deacetylase inhibitor